Peptides as Leverage: The Trade Nobody's Actually Underwriting
Since finishing Ironman Hamburg in June, I've been back in build mode. Copenhagen next summer. A couple of 70.3s and some shorter races between now and then. And every training cycle, without fail, the same conversation surfaces in triathlon and lifting circles.
BPC-157. TB-500. Ipamorelin. People talk about them like they're the next creatine — something you obviously take if you're serious about performance.
The more I sat with it, though, the less it felt like a health question and the more it felt like a deal I'd been handed to underwrite. And once I started running it that way, I noticed something: the tools I already use to evaluate a syndication or a term sheet apply here almost exactly. High achievers are usually excellent at pricing risk. We just seem to stop applying that skill the moment the asset in question is our own bloodstream.
If This Were a Deal, What Would You Need to See First?
"Peptide" is a chemistry term, not a verdict — it tells you nothing about whether a given compound is safe or studied. It helps to sort them into three tiers, the way you'd sort investment opportunities by how much diligence actually backs them.
Tier one is the equivalent of an audited, reviewed offering with a real track record: semaglutide and tirzepatide, the GLP-1s, extensively studied through randomized human trials, approved indications, known dosing.
Tier two is a proven asset deployed in an unproven strategy — approved for one purpose, prescribed off-label for another. Tesamorelin is approved for HIV-related fat loss and gets used off-label by healthy people chasing fat loss and growth hormone support. Thymosin alpha-1 is approved for hepatitis and gets prescribed for vague "immune enhancement." Sermorelin was actually approved once, pulled from the market in 2008, and still circulates through compounding pharmacies.
Tier three is the one driving most of the current hype, and it's the equivalent of a deal with no audited financials, pitched entirely on other investors' testimonials: BPC-157, TB-500, CJC-1295 stacked with ipamorelin, epitalon, MOTS-c, and a growing list of others sold online as "research chemicals." Not one of them has been through a human clinical trial. The cardiologist Eric Topol summarized it plainly: "There is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated."
Would you wire money into a deal with those characteristics — no audited numbers, no track record, pitched purely on conviction? Some investors genuinely do make bets like that, and sometimes that's exactly how outsized returns happen. So the fair question isn't "is this reckless." It's narrower than that: do you actually know the odds here, or are you just trusting the pitch?
A Quick Field Guide
Since these all get lumped together as "peptides" in conversation, it's worth actually knowing what people mean when they say the word. Here's what shows up most often, what it's claimed to do, and how it's typically taken — almost everything outside the GLP-1 category is a self-administered subcutaneous injection, sourced online, dosed by forum consensus rather than a prescriber.
BPC-157 — gut lining repair, tendon and ligament healing, general inflammation. Injection (some oral capsules, thought to be poorly absorbed).
TB-500 (Thymosin Beta-4) — connective tissue repair, flexibility, injury recovery. Injection.
CJC-1295 + Ipamorelin — stacked pair meant to stimulate your own growth hormone release, for recovery and body composition. Injection.
Sermorelin — an older, "gentler" GH-releasing peptide, used for recovery and anti-aging framing. Injection.
Tesamorelin — visceral fat reduction; FDA-approved for HIV-related lipodystrophy, used off-label elsewhere. Injection.
MOTS-c — marketed as mitochondrial and metabolic support, endurance and energy. Injection.
Epitalon — marketed for longevity via telomerase activity. Injection.
GHK-Cu (copper peptide) — collagen production, skin and wound healing. Injection or topical.
Semax / Selank — cognitive enhancement, anxiety reduction, originally developed in Russia. Nasal spray.
Thymosin Alpha-1 — immune "enhancement"; FDA-approved for hepatitis, used off-label elsewhere. Injection.
Melanotan II — tanning, libido. Injection.
PT-141 — libido and sexual dysfunction. Injection or nasal spray.
Semaglutide / Tirzepatide — weight loss, blood sugar regulation (GLP-1/GIP). The tier-one outlier: weekly injection, but the one category here with real trial data behind it.
Is This Leverage?
Leverage, used well, is one of the more powerful tools in investing. You borrow capital to amplify a return you're already confident in. It works because the terms are disclosed — the rate, the covenants, the conditions that trigger a margin call. You know exactly what you're on the hook for if the bet goes wrong.
Tier-three peptides get marketed the same way leverage gets pitched — as a way to amplify what your body would otherwise produce on its own. Faster recovery, more training volume, a shorter runway to the next PR. But nobody can tell you the interest rate. There's no disclosed cost, no known covenant, no clear point at which the "loan" gets called in. The angiogenesis and cell-proliferation mechanisms some of these compounds rely on are the same pathways tumors exploit to grow — not proof of harm, but a real, undisclosed variable sitting somewhere in the fine print you can't actually read.
That's not leverage in the disciplined sense. That's an undisclosed, variable-rate loan, and you won't find out the real rate until you're already several years into repaying it.
Or Is It Just an Unpriced Risk Wearing a Shortcut's Clothes?
There's a real difference between a shortcut and a bet you're calling a shortcut to make it feel smarter.
A genuine shortcut comes from an informational edge — you know the sponsor, you've seen the comps, you understand the market better than the person on the other side of the trade. That's earned speed. Skipping the diligence phase because the underlying information simply doesn't exist yet isn't an edge at all. It's an unpriced bet, dressed up in the language of one.
What the Regulators Actually Think
It's worth knowing how the most sophisticated player in this particular room already prices the risk, even if you end up disagreeing with the conclusion.
The World Anti-Doping Agency doesn't treat "recovery peptide" as a lesser cousin of "anabolic steroid." Steroids sit in category S1. Peptide hormones and growth-hormone secretagogues sit in category S2. Different code, same tier — both banned at all times, in and out of competition, both classified as non-specified substances, the harshest enforcement category there is, with no benefit of the doubt for accidental exposure.
Where that actually gets enforced varies a lot by organization:
Ironman / WTC: Banned at all times for anyone racing under a WADA-signatory ruleset — no ambiguity.
Marathons: World Athletics, the global governing body, is a WADA signatory, so elite and professional fields — Boston, Chicago, New York's pro and invitational races — sit in registered testing pools and are genuinely subject to it. Recreational age-group runners are essentially never tested. The rule exists; the enforcement doesn't reach the back of the field.
Natural bodybuilding federations (WNBF and similar): Peptides are banned right alongside steroids, with real testing behind the rule.
Open / professional bodybuilding (most IFBB Pro-style shows): No testing at all, for anything. Using these compounds there isn't even technically a rules violation, because there's no rule being enforced.
Detection itself splits two ways. A standard workplace or medical drug test — the 5-panel or 10-panel urine screen — won't catch any of this; it's the wrong molecular class entirely, built to catch traditional drugs of abuse. WADA-accredited labs are a different story: mass spectrometry can trace BPC-157 metabolites for roughly four days despite a sub-30-minute half-life, GH secretagogues like the GHRP family for one to two days, and long-acting compounds like CJC-1295 with DAC for two to three weeks or more. Growth hormone itself gets a dual test — a short-window "isoform" test (24 to 36 hours) plus a longer "biomarker" test tracking IGF-1 for two to three weeks — because increasingly, testers don't need to catch the molecule at all. An abnormal hormone pattern over time, the athlete biological passport, is evidence on its own.
For almost everyone reading this, none of that enforcement detail is the actual deciding factor. Nobody is running mass spectrometry on a recreational athlete or a working professional. Which means, for most people, the fear of getting caught was never really the thing holding them back. Strip that fear away entirely, and the only question left is whether the trade still makes sense on the merits.
How Does This Compare to TRT?
A lot of men asking about peptides are really circling the same question from a different angle: what about testosterone replacement therapy? It's worth separating clearly, because TRT sits in a genuinely different evidence category — with one important asterisk.
Testosterone itself has been studied for decades, and recently at real scale. The TRAVERSE trial, published in 2023, randomized over 5,200 men aged 45 to 80 with confirmed hypogonadism and elevated cardiovascular risk to testosterone gel or placebo, and followed them for an average of nearly three years. The primary safety finding was reassuring — no increased risk of the composite endpoint of cardiovascular death, heart attack, or stroke. That's a real, large, randomized human trial. Nothing in tier three has anything close to that.
The asterisk is in the fine print, and it matters. The trial also found more atrial fibrillation, more acute kidney injury, and more pulmonary embolism in the testosterone group — real risks, even in a population with a genuine, lab-confirmed diagnosis. And the lead investigators were explicit that the results apply only to middle-aged and older men with confirmed hypogonadism, under trial-level monitoring. They do not extend to otherwise healthy men with normal-range testosterone chasing an optimization edge, and they don't extend to the higher doses some "low-T" clinics prescribe with far less oversight than a clinical trial provides.
Under anti-doping rules, testosterone is unambiguously S1 — banned at all times, same strict-liability standard as everything else in that category. A therapeutic use exemption exists for athletes with a genuine, well-documented medical diagnosis, but it's a real diagnostic bar to clear, not a formality.
So the honest comparison: TRT for a diagnosed, monitored condition is a fundamentally different trade than a tier-three peptide — it has an actual evidence base behind it. But TRT pursued as lifestyle optimization, through a clinic that skips the diagnostic rigor and the monitoring the trial data actually depends on, starts to resemble the same pattern as everything else in this piece — a real drug, used in a way nobody has actually studied. And it's often the first rung on a ladder: TRT, then a "recovery stack," then a growth-hormone secretagogue, then further into tier three — each step feeling like a small, reasonable extension of the last, until someone's running a protocol they'd never have agreed to if it had been proposed all at once.
The Symmetry Problem
Here's where I want to be careful not to let myself off the hook, because it would be easy to stop the analysis right here and call it objective when it isn't yet.
The self-talk among people using tier-three peptides is remarkably consistent: the FDA is just slow, or captured by industry. I've read the studies myself — meaning the animal studies, because that's all that exists. My guy's been on it for years and he's fine. Everyone in my world is doing it, so it must be fine. None of that is a failure of intelligence. It's intelligence working exactly as designed, in service of a conclusion someone already wanted to reach.
But the same lens has to point at me too, and at anyone reading this who's already decided they're firmly against it. "I'm a physician, so my caution here is just professional rigor" is also a story. It's a story that happens to cost me nothing to believe, flatters my own identity, and conveniently requires no further examination. I don't actually know, with certainty, whether my own hesitation is a fully reasoned calculation or just the version of self-protection I'm most comfortable telling myself. Neither do you, about yours, whichever side of this you land on.
That's the honest starting point. Not "here's why the users are fooling themselves." Both sides of this decision get to ask themselves the same question.
The Underwriting Checklist
If you're actually trying to make this decision rather than just have a reaction to it, these are the questions I'd bring to any deal, applied here without the euphemism:
What's my margin of safety — is the downside genuinely capped, or is it open-ended and unknown? What's the real leverage ratio — how much marginal upside am I borrowing against how much unpriced, unmeasurable liability? Who's actually on the other side of this trade, and do they profit whether or not it works out for me? Would I make this exact bet with someone else's capital, under a fiduciary duty — an LP's money, my kids' inheritance, my own body a decade from now? And underneath all of it: am I underwriting this myself, or am I just borrowing the room's confidence and calling it my own conclusion?
Where I've Landed — For Now
I haven't taken this trade. Not because I've concluded with certainty that it's wrong for everyone — I don't think the evidence supports that level of confidence in either direction yet. It's that on the information currently available to me, the deal doesn't underwrite. The disclosed terms don't exist. The downside isn't capped. And I'd rather wait for better information than be the guy who found out the hard way what the actual interest rate was.
That might change as the research catches up — tier one proves the underlying biology can eventually deliver once it's properly studied. But that's a different trade than the one being sold right now.
Where do you land once you run your own numbers?